MARKETING ANALYSIS OF THE PHARMACEUTICAL MANUFACTURING INDUSTRY

2016 ◽  
Vol 16 (4) ◽  
pp. 81-86
Author(s):  
James Walton ◽  
Andrew Mason ◽  
Kevin Mason
2018 ◽  
Vol 8 (12) ◽  
pp. 2700 ◽  
Author(s):  
Hungyen Lin ◽  
Zijian Zhang ◽  
Daniel Markl ◽  
J. Zeitler ◽  
Yaochun Shen

Optical coherence tomography (OCT) has recently attracted a lot of interest in the pharmaceutical manufacturing industry as a fast, contactless and non-destructive modality for quantifying thin film coatings on pharmaceutical dosage forms, which cannot be resolved easily with other techniques. In this topical review, we present an overview of the research that has been performed to date, highlighting key differences between systems and outlining major challenges ahead.


2015 ◽  
Vol 19 (2) ◽  
pp. 296-314 ◽  
Author(s):  
Athar Mahmood Ahmed Qureshi ◽  
Nina Evans

Purpose – This study aims to explore deterrents to knowledge-sharing in pharmaceutical manufacturing. Effective knowledge-sharing is fundamental to stimulation of the process of knowledge absorption. The limited proximal communication between the employees in the pharmaceutical industry stifles their knowledge-sharing behaviour significantly. Design/methodology/approach – A cross-sectional case study, consisting of semi-structured interviews with managers and scientists, was conducted in a multinational pharmaceutical company in Australia. Respondents were asked to answer questions regarding their current knowledge-sharing practices and to identify organisational deterrents to knowledge-sharing. The data were condensed into themes according to the thematic analysis method. Findings – The pharmaceutical industry is extensively regulated and its excessive competitiveness is cultivating organisational reticence towards the development of a knowledge-sharing culture. Nine categories of deterrents to intra- (within) and inter-organisational (between organisations) knowledge-sharing have been identified. These categories include high cost of sharing knowledge, information technology limitations, knowledge-hiding, lack of socialisation, lack of trust culture, non-educational mindset, organisational politics, poor leadership and time pressure. Research limitations/implications – The population of this study consists of managers and practitioners working for a pharmaceutical company. Hence, the generalisability of the findings to other health-care settings is unknown. Practical implications – The findings have implications for leaders and managers who should be aware of these professional diversities, instigators as well as the ripple effects of limited knowledge-sharing to guide the organisation towards developing an optimal knowledge-sharing culture. Originality/value – A focussed investigation of knowledge-sharing behaviour within the pharmaceutical industry in Australia, considering the pressure applied to this industry over the past decade. This case study specifically focusses on the diversity of deterrents to knowledge-sharing in the pharmaceutical manufacturing industry.


2021 ◽  
Vol 2021 ◽  
pp. 1-10
Author(s):  
Su Wang ◽  
Yuwen Chen

In recent years, a new generation of information technology has provided sufficient technical support for the smart manufacturing industry. In order to promote the upgrading of China’s pharmaceutical smart manufacturing industry, the direction of industrial upgrading and transformation will be discussed from the perspective of technological innovation. According to the input and output data of technological innovation in China’s pharmaceutical manufacturing industry from 2007 to 2019, the DEA method is used to analyze the allocation of innovative resources in China’s pharmaceutical manufacturing industry in recent years. The study found that the efficiency of technological innovation in China’s pharmaceutical manufacturing industry fluctuated greatly from 2007 to 2019, with a low overall level and varying degrees of wasted resources. On this basis, an in-depth analysis of the system architecture of the pharmaceutical smart manufacturing industry under the Industry 4.0 environment was performed. Finally, four paths for the digital transformation of China’s pharmaceutical manufacturing industry are proposed. Chinese pharmaceutical manufacturing companies need to use new technologies to carry out comprehensive intelligent upgrading and digital transformation to improve innovation efficiency.


2011 ◽  
Vol 63 (7) ◽  
pp. 1441-1445 ◽  
Author(s):  
S. R. Sitre ◽  
S. Satyanarayan

In India a large number of pharmaceutical industries are manufacturing drugs of complex type subsequently producing huge quantities of wastewaters. The herbal pharmaceutical industries are one of them which manufacture various herbal medicines from natural products and certain chemicals and metal combinations. During their manufacturing process a large number of toxicants enter the watercourse harming the biota of the receiving water bodies. Zooplankton organisms being at the base of the food chain if affected, will subsequently affect the fisheries potential at large, harming the interest of man. Keeping this point in view a herbal pharmaceutical manufacturing industry based at Nagpur was selected for investigation with respect to assessing its toxic effect on the freshwater crustacean Cypris spp. during short duration toxicity tests. This research paper discusses in detail the bioassay evaluation of raw, neutralized and physico-chemically treated herbal pharmaceutical effluent for arriving at a concentration safe for the Cypris spp.


Author(s):  
Jose Arturo Garza-Reyes ◽  
Ioannis E. Betsis ◽  
Vikas Kumar ◽  
Moh’d Anwer Radwan Al-Shboul

Purpose The purpose of this paper is to assess the quality practices of European pharmaceutical manufacturers to determine the level of readiness of this industrial sector to implement and/or sustain lean manufacturing (LM). Design/methodology/approach An assessment framework developed by Al-Najem et al. (2013) was adapted to evaluate how ready European pharmaceutical manufacturers are to implement and/or sustain LM. Therefore, the lean readiness (LR) level of these organisations was assessed through six quality practices related to LM. These included: processes, planning and control, human resources, top management and leadership, customer relations, and supplier relations. One research question and three hypotheses were formulated and tested using a combination of descriptive statistics and non-parametric Mann-Whitney tests. Data were collected through a survey questionnaire distributed to 310 European pharmaceutical manufacturers and responded by 37 of these organisations. Findings Overall, the results of this study indicate an inadequate level of LR for the participating firms. Simultaneously, it was concluded that factors such as company size, type of relationships with suppliers and ISO 9000 certification do not have an effect on the quality practices, and hence LR level, of European pharmaceutical manufacturing organisations. Practical implications This study provides crucial information regarding the LR level of European pharmaceutical manufacturers, which can now be aware of the areas in their practices that require further improvement towards a successful lean journey. Simultaneously, organisations in the pharmaceutical sector that intend to implement LM can consider the results of this study and evaluate their readiness level. Managers can, therefore, refer to this research and use it as a platform to take better decisions regarding what quality aspects of their operations need to be enhanced to successfully deploy or sustain a lean strategy. Originality/value This research is one of the very few studies that have focussed on evaluating whether the European pharmaceutical manufacturing industry is ready to successfully implement or sustain LM. Therefore, this research expands the limited existent body of knowledge of LM in this industry.


Sign in / Sign up

Export Citation Format

Share Document